Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
A phase 3 trial of Trastuzumab deruxtecan, Pembrolizumab and Trastuzumab in gastric & gastro-oesophageal junction cancer, run by Daiichi Sankyo, now recruiting.
Overview
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer is a phase 3 interventional study registered as NCT06731478 by Daiichi Sankyo, with 726 participants planned, started 2025-02-27 and due to reach its primary completion in 2028-06-01. Interventions recorded: Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab and Chemotherapy.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Shares Merck & Co. (MSD), Gastric & gastro-oesophageal junction cancer, Pembrolizumab and the tag pipeline.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Trastuzumab, Trastuzumab deruxtecan, Gastric & gastro-oesophageal junction cancer, Pembrolizumab and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Daiichi Sankyo, Trastuzumab, Trastuzumab deruxtecan, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Shares Daiichi Sankyo, Merck & Co. (MSD), Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Shares Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
- TrialA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Merck & Co. (MSD) and the tag pipeline.
- TrialSafety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Shares Daiichi Sankyo, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.